

ImmuCast

Release Notes

v5.18.7.1

Support Services

For general support on this product, contact your system administrator or help desk. For up-to-date documentation, visit the STC Documentation Portal at https://documentation.stchome.com/.

Connect with Us on Social Media

Copyrights and Trademarks

This documentation describes the following: ImmuCast 5.18.7.1 (and IWeb Forecaster) release notes

Table of Contents

Introduction

This release contains schedule changes that may affect the group of patients you select to be reforecasted. Detailed descriptions and test cases follow below in the ticket descriptions.

Please note that testing scenarios do not have a grace period applied.

Also note that Forecast, Forecaster, and ImmuCast are used interchangeably throughout this document.

Apply the Release

Apply the release by executing either the included `forecast.bat` or `forecast.sh` file. Prior forecast releases through version 5.18.1 should have already been applied. Log files, which are created in the same folder from where the release is executed, can be reviewed for errors. This release is only dependent upon previously applying v5.18.1. Versions 5.18.5 and 5.18.7 do not need to be applied. If those versions have already been applied, this release will replace them automatically.

To determine the current version of ImmuCast, execute this statement from SQLPlus:

```
SQL> select max(version) from h33_forecast_version where insert_stamp =
(select max(insert_stamp) from h33_forecast_version);
```

If the version number returned is not 5.18.1 or later, download and apply the previous releases prior to applying this. If any of the prior 5.18.x releases were not applied, edit the `forecast.bat` file (or `forecast.sh` if applying the batch with the shell script) and uncomment any lines with a later version number than the version number returned by your query so that they can be applied to the database. Log files are created in the folder from where the release is executed and can be reviewed for errors.

For example, if the release for 5.18.1 was not applied, uncomment that line in the file to include it when the release is executed:

```
REM sqlplus H33ASIIS/ASIIS@SIIS @forecast_patch5_18_1.sql
```

For ImmuCast (Stand-Alone Forecaster)

After applying the release, restart Tomcat to enable and cache any new vaccine codes into memory.

For IWeb Only

The database should be reforecast when there have been multiple changes to forecasting. Please be aware that this can affect a large number of patients and is best accomplished over a weekend.

IWeb versions prior to 5.17.5.2: Patients that are marked for reforecasting may interfere with the immediate deduplication of HL7 messages, because patients belonging to a particular organization will also be picked up by that organization's immediate deduplication session. Reforecasting patients in IWeb version 5.17.5.2 or later will not affect the deduplication of HL7 messages.

If IWeb is hosted by STC, please contact the Help Desk to ask that the current v5.18.7.1_PreIWeb5.17.5.2_NeedsForecast.sql script included in this release be executed to mark patients for reforecasting. This will update the patients affected by this release. Non-STC hosted clients may perform these steps to mark patients for reforecasting.

After applying the database release, log in to SQLPlus as the H33ASIIS user. Execute the v5.18.7.1_PreIWeb5.17.5.2_NeedsForecast.sql script included with this release to flag the patients affected by this release for reforecasting.

If you desire to reforecast all patients, please execute the H33_MARK_FORECAST procedure (`SQL> exec h33_mark_forecast`) to flag patient records to be reforecast. The procedure may also be run for a specific birth date range. For IWeb 5.17.5.2 or later, forecasting is run during the regular nightly deduplication processes.

Age Groups Affected by this Release – v5.18.7.1

If your database will be reforecast for this release, the following are age ranges that we believe to be most affected by the changes in this release. You may wish to limit your reforecast to these age ranges to limit the scope of your reforecast. Based on the information below, the range for reforecasting would be 0 to 24 years of age. Based on your experience and knowledge of your patients, you may choose a different age range.

- DTaP – Patient current age >= 4 years and < 7 years of age.

Ticket Details – 5.18.7.1

The following lists the detailed information about each of the tickets addressed in v5.18.7.1:

Ticket #	Affects Client	Description
FCAST-495 HDLA-1805 HDTN-1031	All	**DTaP –** Forecast for Tdap booster following DTaP #5 at 4 years of age with an evaluation date of < 7 years of age returned a NULL value in Due Date and Minimum Date in the v5.18.7 release.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
DTaP #5 at 4 years of age and evaluation date < 7 years of age.	04/09/2013	M	DTaP (CVX 20)	06/07/2013	Y				
			DTaP (CVX 20)	09/04/2013	Y				
			DTaP (CVX 20)	08/08/2014	Y				
			DTaP (CVX 20)	05/20/2015	Y				
			DTaP (CVX 20)	08/08/2017	Y	04/09/2024	04/09/2024	04/09/2026	Tdap recommended at 11 yrs of age.
Evaluation date < 7 years of age.	01/01/2012	F	DTaP (CVX 20)	03/02/2012	Y				
			DTaP (CVX 20)	05/03/2012	Y				

				DTaP (CVX 20)	06/21/2012	Y				
				DTaP (CVX 20)	04/05/2013	Y	01/01/2016	01/01/2016	01/01/2019	DTaP #5 recommended at 4 yrs of age.
No DTaP history. Evaluation date < 7 years of age.	01/01/2014	F					03/01/2014	02/01/2014	04/01/2014	DTaP #1 recommended at 2 mos. of age.
Dose 1 DTaP at >= 48 months of age. Evaluation date < 7 years of age.	01/01/2014	F	DTaP (CVX 20)	07/20/2018	Y	08/17/2018	08/17/2018	09/16/2018	DTaP #2 recommended at 28 day interval from DTaP #1.	
Dose 5 DTaP at >= 48 months of age. Evaluation date < 7 years of age.	01/01/2014	F	DTaP (CVX 20)	03/01/2014	Y					
			DTaP (CVX 20)	05/01/2014	Y					
			DTaP (CVX 20)	07/01/2014	Y					
			DTaP (CVX 20)	01/01/2015	Y					

				DTaP (CVX 20)	01/01/2018	Y	01/01/2025	01/01/2025	01/01/2027	Tdap recommended at 11 yrs of age.

FCAST-497	All	**DTaP –** DTaP forecast was not correct with evaluation date >= 4 years of age.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Evaluation date >= 4 years of age	06/23/2014	F	DTaP-HepB-IPV (CVX 110)	10/28/2014	Y				
			DTaP-HepB-IPV (CVX 110)	12/30/2014	Y	01/27/2015	01/27/2015	02/26/2015	DTaP #3 recommended at 28 day interval from DTaP #2
Evaluation date >= 4 years of age	07/16/2014	F	DTaP-Hib-IPV (CVX 120)	09/22/2014					
			DTaP-Hib-IPV (CVX 120)	11/25/2014					
			DTaP-Hib-IPV (CVX 120)	01/19/2015					
			DTaP-Hib-IPV (CVX 120)	10/16/2015					
			DTaP-IPV (CVX 130)	07/19/2018	Y	07/16/2025	07/16/2025	07/16/2027	Tdap forecast at 11 yrs of age

Ticket Details – 5.18.7

The following lists the detailed information about each of the tickets addressed in the v5.18.7 release. Please note that dates in **red** have been revised from the original v5.18.7 release notes provided on 07/13/2018.

Ticket #	Affects Client	Description
FCAST-485 HDSAF-132	All	**HPV –** Two dose HPV schedule for patients beginning the series at < 15 years of age was not showing as complete with dose 2 administered at appropriate interval in v5.18.5 release.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
HPV Two Dose Schedule (< 15 years of age)	07/10/2005	F	HPV9 (CVX 165)	09/14/2016	Y	03/14/2017	02/14/2017	09/14/2017	
			HPV9 (CVX 165)	03/15/2017	Y				Complete
HPV with interval between doses 1 and 2 < 5 months	07/10/2005	F	HPV9 (CVX 165)	09/14/2016	Y	03/14/2017	02/14/2017	09/14/2017	
			HPV9 (CVX 165)	01/01/2017	Y	03/26/2017	03/26/2017	04/25/2017	Patient is moved to 3 –dose schedule
			HPV9 (CVX 165)	03/26/2017	Y				Complete

	HPV series started < 15 yrs of age. Patient age now > 15 yrs.	01/01/2001	F	HPV quadrivalent (CVX 62)	02/01/2013	Y	08/01/2013	07/01/2013	02/01/2014	
				HPV9 (CVX 165)	01/01/2018	Y				Complete
	HPV series started at >= 15 years of age	01/01/1999	M	HPV quadrivalent (CVX 62)	03/01/2015	Y	04/26/2015	03/29/2015	10/26/2015	Patient is on 3-dose schedule
				HPV quadrivalent (CVX 62)	05/01/2015	Y	09/01/2015	08/01/2015	10/01/2015	
				HPV quadrivalent (CVX 62)	09/01/2015	Y				Complete

FCAST-484 HDSAF-131 HDSAF-137	All	**Tdap –** Tdap administered at >= 11 years of age was displaying an incorrect forecast date for the Td booster dose in v5.18.5 release.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Tdap at >= 11 yrs of age. Td forecast 10 years later	09/18/2004	M	DTaP Unspec (CVX 107)	11/18/2004	Y				
			DTaP Unspec (CVX 107)	01/13/2005	Y				
			DTaP Unspec (CVX 107)	03/30/2005	Y				

			DTaP Unspec (CVX 107)	03/27/2006	Y				
			DTaP Unspec (CVX 107)	11/18/2008	Y	09/18/2015	09/18/2015	**09/18/2017**	
			Tdap (CVX 115)	11/07/2016	Y	11/07/2026	11/07/2021	12/07/2026	
Tdap at >= 11 yrs of age. Td forecast 10 years later	07/02/2002	F	DTaP-Hib (CVX 50)	11/12/2002	Y				
			DTaP-5 Pertussis (CVX 106)	04/02/2003	Y				
			DTaP (CVX 20)	01/30/2003	Y				
			DTaP-5 Pertussis (CVX 106)	10/13/2003	Y				
			DTaP-5 Pertussis (CVX 106)	07/11/2006	Y	07/02/2013	07/02/2013	**07/02/2015**	
			Tdap (CVX 115)	07/26/2013	Y	07/26/2023	07/26/2018	08/25/2023	
Tdap at >= 11 yrs of age. Td forecast 10 years later	12/29/2000	M	DTaP-5 Pertussis (CVX 106)	02/27/2001	Y				

			DTaP-5 Pertussis (CVX 106)	05/01/2001	Y				
			DTaP-5 Pertussis (CVX 106)	07/17/2001	Y				
			DTaP-5 Pertussis (CVX 106)	04/01/2002	Y				
			DTaP-5 Pertussis (CVX 106)	01/25/2004	N	12/29/2007	12/29/2007	01/28/2008	Invalid Vaccination: Minimum age for this dose not met.
			Tdap (CVX 115)	06/28/2012	Y	06/28/2022	06/28/2017	07/28/2022	
Tdap at >= 11 yrs of age. Td forecast 10 years later	02/22/2002	F	DTaP-5 Pertussis (CVX 106)	04/22/2002	Y				
			DTaP-5 Pertussis (CVX 106)	08/23/2002	Y				
			DTaP-5 Pertussis (CVX 106)	11/25/2002	Y				
			DTaP-5 Pertussis (CVX 106)	06/23/2003	Y				
			DTaP-5 Pertussis (CVX 106)	06/30/2006	Y	02/22/2013	02/22/2013	**02/22/2015**	
			Tdap (CVX 115)	08/18/2014	Y	08/18/2024	08/18/2019	09/17/2024	

Tdap at >= 11 yrs of age. Td forecast 10 years later	09/18/2004	F	DTaP Unspec (CVX 107)	11/18/2004	Y				
			DTaP Unspec (CVX 107)	01/13/2005	Y				
			DTaP Unspec (CVX 107)	03/30/2005	Y				
			DTaP Unspec (CVX 107)	03/27/2006	Y				
			DTaP Unspec (CVX 107)	11/18/2006	N	09/18/2011	09/18/2011	10/18/2011	Invalid Vaccination: Minimum age for this dose not met.
			Tdap (CVX 115)	11/07/2016	Y	11/07/2026	11/07/2021	12/07/2026	
Tdap at >= 11 yrs of age. Td forecast 10 years later	02/26/2003	M	DTaP Unspec (CVX 107)	06/26/2003	Y				
			DTaP Unspec (CVX 107)	08/28/2003	Y				
			DTaP Unspec (CVX 107)	06/22/2004	Y				
			DTaP Unspec (CVX 107)	05/27/2008	Y	02/26/2014	02/26/2014	**02/26/2016**	
			Tdap (CVX 115)	05/04/2015	Y	05/04/2025	05/04/2020	06/03/2025	

Tdap at >= 11 yrs of age. Td forecast 10 years later	03/21/2001	M	DTaP Unspec (CVX 107)	05/24/2001	Y				
			DTaP Unspec (CVX 107)	07/30/2001	Y				
			DTaP Unspec (CVX 107)	09/29/2001	Y				
			DTaP Unspec (CVX 107)	10/23/2002	Y				
			DTaP Unspec (CVX 107)	03/22/2006	Y	03/21/2012	03/21/2012	**03/21/2014**	
			Tdap (CVX 115)	03/29/2012	Y	03/29/2022	03/29/2017	04/28/2022	

FCAST-483 HDWA-3167 FCAST-486 HDSAF-134	All	**Polio –** Dose #3 at 48 months of age with 6 month interval from Dose #2 was not counted as complete when in a mixed schedule of OPV and IPV and/or DTaP-IPV exists in immunization history.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
History of OPV and IPV. Dose #3 at 48 mos of age.	12/30/2012	F	OPV (CVX 2)	12/12/2013	Y				

				OPV (CVX 2)	04/08/2016	N				(Trivalent OPV is no longer available) Invalid: OPV bivalent and OPV monovalent are not acceptable for Polio series
				DTaP-Hib-IPV (CVX 120)	10/25/2016	Y				
				DTaP-IPV (CVX 130)	08/08/2017	Y				Complete
	Dose #3 at 48 mos of age.	12/20/2004	M	IPV (CVX 10)	04/14/2005	Y				
				DTaP-HepB-IPV (CVX 110)	06/21/2005	Y				
				DTaP-IPV (CVX 130)	12/22/2008	Y				Complete

FCAST-488 FCAST-442 HDMT-1841	All	**DTaP –** DtaP #4 did not forecast Dose #5 when administered at >= 4 years of age with a 4 month interval from Dose #3. To be considered complete for primary series, the 4th dose must meet the 6 month interval from Dose #3.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
DTaP #4 at >= 48 mos., less than 6 month interval from Dose #3	02/01/2013	M	DTaP (CVX 20)	05/12/2013	Y				
			DTaP (CVX 20)	08/15/2016	Y				

			DTaP (CVX 20)	11/15/2017	Y				
			DTaP (CVX 20)	03/15/2018	Y	09/15/2018	09/15/2018	02/01/2020	DTaP #5 is forecast.
			DTaP (CVX 20)	09/15/2018	Y	02/01/2024	02/01/2024	02/01/2026	Tdap booster recommended at 11 yrs of age.
DTaP #4 at >= 48 mos., meets 6 month interval from Dose #3	02/01/2012	M	DTaP (CVX 20)	05/12/2012	Y				
			DTaP (CVX 20)	08/15/2015	Y				
			DTaP (CVX 20)	11/15/2015	Y				
			DTaP (CVX 20)	06/15/2016	Y	**02/01/2023**	**02/01/2023**	**02/01/2025**	Dose 4 at >= 4 yrs of age. Dose 5 is not needed. Tdap forecast at 11 yrs of age.

Ticket Details – 5.18.5

The following lists the detailed information about each of the tickets addressed in v5.18.5 release. Please note that dates in **red** have been revised from the original v5.18.5 release notes provided on 05/29/2018.

Ticket #	Affects Client	Description
FCAST-479 HDAZ-898	All	Updated vaccine description from zoster to zoster live. This will only display in IWeb lists and screens.
FCAST-469 HDTN-985 HDWA-3131 HDWV-1029	All	**Polio –** Forecast interval from a live vaccine was assuming 28 days for OPV. Since IPV is the vaccine currently available, the 28 day live vaccine interval is now only included in the evaluation of immunization history and not in the forecast of future doses. This change could affect patients < 18 years of age.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Polio forecast with live vaccine	01/01/2014	F	No History			03/01/2014	02/12/2014	04/01/2014	Polio #1 Forecast with no History
			Varicella (CVX 21)	03/28/2018	Y				Polio #1 forecast remains as: Rec Date: 03/01/2014 Min Date: 02/12/2014 Past Due: 04/01/2014
Polio forecast with live vaccine	11/22/2004	F	IPV (CVX 10)	01/17/2005	Y				
			IPV (CVX 10)	04/05/2005	Y				

				IPV (CVX 10)	05/07/2005	Y	11/22/2008	11/22/2008	11/22/2011	Polio #4 forecast does not change with addition of live vaccines MMR and Varicella
				MMR (CVX 3)	05/18/2006	Y				
				MMRV (CVX 94)	04/17/2018	Y				

FCAST-440 HDWA-3065	All	**Polio –** Number of doses in test case exceeded number of doses in the schedule rows and the extra dose was marked as invalid. The polio schedules have been modified to evaluate up to 7 doses.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Polio with excessive number of doses	01/05/2007	F	OPV (CVX 02)	01/21/2007	N				Minimum age not met.
			OPV (CVX 02)	02/21/2007	Y				
			OPV (CVX 02)	03/21/2007	Y				
			OPV (CVX 02)	04/21/2007	Y				
			OPV (CVX 02)	05/26/2007	Y				
			OPV (CVX 02)	07/02/2008	Y				Warning: This dose is not needed (The warning is because it is an additional dose before the 4th birthday)

				IPV (CVX 10)	10/11/2013	Y				Series Complete

FCAST-449 HDWA-3088 HDWY-1388 HDMS-1663	All	**Hib –** Issue when dose 1 administered prior to 7 months of age and dose 2 administered after 7 months of age putting patient into 3 dose schedule instead of remaining in 4 dose schedule

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Hib Dose 1 prior to 7 months of age with dose 2 >= 7 months of age	03/01/2017	M	Hib PRP-T (CVX 48)	05/19/2017	Y				
			Hib PRP-T (CVX 48)	10/05/2017	Y	11/30/2017	11/02/2017	12/30/2017	Child remains on 4 dose schedule
Hib Dose 1 prior to 7 months of age with dose 2 >= 7 months of age	03/04/2017	F	Hib PRP-T (CVX 48)	04/25/2017	Y				
			Hib PRP-T (CVX 48)	10/25/2017	Y	12/20/2017	11/22/2017	01/19/2018	Child remains on 4 dose schedule

	Hib Dose 1 prior to 7 months of age with dose 2 >= 7 months of age	07/18/2017	M	Hib PRP-T (CVX 48)	08/29/2017	Y				
				Hib PRP-T (CVX 48)	03/07/2018	Y	05/02/2018	04/04/2018	06/01/2018	Child remains on 4 dose schedule

FCAST-443 HDWA-3072	All	**Hib –** Patients receiving dose 3 at 12 months of age – 4 days were being forecast for dose 4. These patients will now show as Complete with dose #3.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Hib Dose 3 administered at 12 mos – 1 day	11/18/2015	M	Hib PRP-T (CVX 48)	01/19/2016	Y				
			Hib PRP-T (CVX 48)	03/18/2016	Y				
			Hib PRP-T (CVX 48)	11/17/2016	Y				Complete with dose 3 at 12 months of age

FCAST-459 HDWY-1407 HDAZ-890	All	**Hib –** Patient receiving dose 2 at 11+ months of age was requiring a 56 day interval to dose 3 so it could be counted as final dose in series. Correction has been made to forecast 4 week minimum interval (8 week recommended for primary series).

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Hib dose 2 at 11 months of age	02/10/2017	F	Hib PRP-OMP (CVX 49)	04/25/2017	Y				
			Hib PRP-T (CVX 48)	01/03/2018	Y	02/28/2018	01/31/2018	03/30/2018	
			Hib PRP-T (CVX 48)	02/07/2018	Y	04/04/2018	04/04/2018	06/10/2018	

Hib dose 2 at 12 months - of age	03/09/2017	F	Hib PRP-T (CVX 48)	04/25/2017	Y				
			Hib PRP-OMP (CVX 49)	03/16/2018	Y	05/11/2018	05/11/2018	07/09/2018	Dose was previously marked as invalid
	01/10/2017	M	Hib PRP-T (CVX 48)	12/13/2017	Y				
			Hib PRP-T (CVX 48)	01/10/2018	Y	03/07/2018	03/07/2018	05/10/2018	Dose was previously marked as invalid

FCAST-478

All

HepB Adjuvanted - 2 dose (Heplisav-B (HepB-CpG) Recommendations

https://www.cdc.gov/mmwr/volumes/67/wr/mm6715a5.htm?s_cid=mm6715a5_w

Approved for >= 18 years of age. Minimum interval between dose 1 and dose is 4 weeks. Recommended interval is 1 month.

"The 2-dose HepB vaccine series only applies when both doses in the series consist of HepB-CpG. Series consisting of a combination of 1 dose of HepB-CpG and a vaccine from a different manufacturer should consist of 3 total vaccine doses and should adhere to the 3-dose schedule minimum intervals of 4 weeks between dose 1 and 2, 8 weeks between dose 2 and 3, and 16 weeks between dose 1 and 3. Doses administered at less than the minimum interval should be repeated. However, a series containing 2 doses of HepB-CpG administered at least 4 weeks apart is valid, even if the patient received a single earlier dose from another manufacturer."

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
HepB Adjuvanted - 2 dose	01/01/1998	M	Heplisav-B (CVX 189)	01/01/2018	Y	01/29/2018	01/29/2018	02/28/2018	
			Heplisav-B (CVX 189	02/01/2018	Y				Complete

HepB Adjuvanted Dose 1 and Dose 2 as HepB Adult. (3 dose schedule now applies)	01/01/1998	M	Heplisav-B (CVX 189)	01/01/2018	Y	01/29/2018	01/29/2018	02/28/2018	
			HepB Adult (CVX 43)	02/01/2018	Y	04/23/2018	04/23/2018	05/23/2018	Patient is moved to 3 dose schedule.
			HepB Adult (CVX 43)	04/23/2018	Y				Complete
HepB Adult dose 1, HepB Adjuvanted as Dose 2 and HepB Adult Dose 3. (3 dose schedule now applies.	01/01/1998	M	HepB Adult (CVX 43)	01/01/2018	Y	01/29/2018	01/29/2018	02/28/2018	
			Heplisav-B (CVX 189)	02/01/2018	Y	04/23/2018	04/23/2018	05/23/2018	Patient is moved to 3 dose schedule
			HepB Adult (CVX 43)	04/23/2018	Y				Complete

	HepB Adult dose 1, HepB Adjuvanted as Dose 2 and Dose 3. (3 dose schedule applies but doses 2 and 3 can meet min interval of 28 days).	01/01/1998	M	HepB Adult (CVX 43)	01/01/2018	Y	01/29/2018	01/29/2018	02/28/2018	
				Heplisav-B (CVX 189)	02/01/2018	Y	04/23/2018	04/23/2018	05/23/2018	Patient is moved to 3 dose schedule.
				Heplisav-B (CVX 189)	03/01/2018	Y				Meets 28 day interval between 2 doses of Heplisav-B Complete
	HepB Adult dose 1, HepB Adjuvanted as Dose 2 and HepB Adult Dose 3. (3 dose schedule applies but doses 1 and 3 can meet min interval of 28 days)	01/01/1998	M	Heplisav-B (CVX 189)	01/01/2018	Y	01/29/2018	01/29/2018	02/28/2018	
				HepB Adult (CVX 43)	02/01/2018	Y	04/23/2018	04/23/2018	05/23/2018	Patient is moved to 3 dose schedule.

				Heplisav-B (CVX 189)	03/01/2018	Y				Meets 28 day interval between 2 doses of Heplisav-B Complete

FCAST-463 HDWY-1429	All	**Zoster – IWeb -** Updated vaccine family name from Herpes Zoster to Zoster to match CDC vaccine group name. The display name change does not apply to the ImmuCast UI. Informational warning message added to Dose 1, zoster live to reduce confusion among providers when doses 2 and 3 of zoster are recommended. "zoster, live should be followed by 2 doses of zoster, recombinant vaccine"

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Zoster , live followed by zoster , recombinant	01/01/1950	F	zoster, live (CVX 121)	01/01/2018	Y	03/01/2018	02/26/2018	03/31/2018	Warning: zoster, live should be followed by 2 doses of zoster, recombinant vaccine
			Zoster, recom-binant (CVX 187)	03/01/2018	Y	05/01/2018	03/29/2018	05/31/2018	
			Zoster, recom-binant (CVX 187)	05/01/2018	y				Complete

FCAST-471 HDTN-979	All	**Zoster Unspecified –** Zoster unspecified is now associated with the zoster, recombinant (2 dose) schedule. Corrected issue that associated zoster unspecified to the Adolescent HepB 2 dose vaccine group. This did not affect the zoster or HepB forecast but returned a HepB invalid reason along with the vaccination validation for Zoster unspecified.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
Zoster , unspecified	01/01/1950	F	zoster, unspec. (CVX 188)	01/01/2018	Y	03/01/2018	01/29/2018	03/31/2018	
			zoster, unspec. (CVX 188)	03/01/2018	Y				Complete

FCAST-442 HDWA-3069	All	**DTaP –** Updated Best Practice Guidelines related to DTaP Interval between Dose 3 and Dose 4 ACIP does allow the 4-day grace period to be applied retrospectively when the fourth dose of DTaP has been administered with only a 4-month interval from the third dose. The forecast was not applying the grace period to the dose validation when the interval between doses 3 and 4 was 4 months – 4 days.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
DTaP #4 administered with 4 month-4 day interval from DTaP #3	02/15/2016	F	DTaP (CVX 20)	04/11/2016	Y				
			DTaP (CVX 20)	06/15/2016	Y				
			DTaP (CVX 20)	02/15/2017	Y				
			DTaP (CVX 20)	06/11/2017	Y				Dose 4 administered at 4 months – 4 days Warning: The minimum recommended interval between DTaP-3 and DTaP-4 is 6 months. However, DTaP-4 need not be repeated if administered at least 4 months after DTaP-3.

FCAST-465 HDTN-978 HDWA-3129	All	**Tdap –** Patients with DTaP #4 at >= 4 years of age were being forecast for Tdap at 7 years of age. Correction has been made to forecast Tdap for those patients at 11 years of age.

HDLA-1749		

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
DTaP #4 administered at >= 4 years of age	01/01/2013	F	DTaP (CVX 20)	03/01/2013	Y				
			DTaP (CVX 20)	05/01/2013	Y				
			DTaP (CVX 20)	07/01/2013	Y				
			DTaP (CVX 20)	01/01/2017	F	01/01/2024	01/01/2024	**01/01/2026**	Tdap recommended at 11 years of age
DTaP #4 administered at >= 4 years of age	06/23/2012	M	DTaP (CVX 20)	10/05/2012	Y				
			DTaP (CVX 20)	05/30/2013	Y				
			DTaP (CVX 20)	07/28/2017	Y				
			DTaP (CVX 20)	02/26/2018	Y	06/23/2023	06/23/2023	**06/23/2005**	Tdap recommended at 11 years of age

FCAST-457 HDWY-1407	All	**Pneumococcal Conjugate –** Issue with dose 2 administered at >= 7 months of age with dose 1 administered at < 7 months of age. Interval from dose 2 to 3 was being forecast at 4 weeks instead of 8.

Scenario	DOB	Gender	Antigen	Vacc Date	Valid	Rec Date	Min Date	Past Due	Comments
PCV-13 dose 1 at < 7 mos, dose 2 at >= 7 mos.	02/10/2017	F	PCV-13 (CVX 133)	04/25/2017	Y	06/20/2017	05/23/2017	07/20/2017	

				PCV-13 (CVX 133)	01/03/2018	Y	02/28/2018	02/28/2018	06/10/2018	Dose 2 at >= 7 months of age. 8 week interval to Dose 3 (and 12 mos min age)
				PCV-13 (CVX 133)	02/28/2018	Y				Complete

Product Documentation

Product documentation is located on the STC Documentation Portal: https://documentation.stchome.com/.

The following documents are available for this version of ImmuCast:

- ImmuCast 5.18.1 User Guide
- ImmuCast 5.18.7.1 Release Notes